The Foundation was established by Trond Mohn in a foundation deed dated 22 December 2004. By a decision of the Board of 3 October 2013, subsequently approved by the Norwegian Foundation Authority, the assets, rights and obligations of Bergen Research Foundation and the Frank Mohn Foundation were transferred to Bergen Medical Research Foundation through a merger. The merged Foundation continued to use the name Bergen Research Foundation. The name of the Foundation was changed to the Trond Mohn Foundation with effect from 1 January 2019.
The general objective of the Foundation is to support research and initiatives that promote research at the University of Bergen and in Helse Bergen Health Trust.
It is also the Foundation’s objective to support research at the intersection between basic research and clinical medical activities, both at the University of Bergen and in Helse Bergen Health Trust, in accordance with the Foundation’s objective prior to the merger mentioned in Article 1.
The Foundation can also support research and initiatives that promote research at other research institutions in Norway in cooperation with institutions based in Bergen.
The Foundation’s founding capital is NOK 305 million. NOK 297 million of the founding capital shall be irrevocable.
The Foundation’s funds shall be invested and managed to achieve the best possible return and adequate security, and in such a way as to ensure long-term capital accumulation.
Exceptions can be made from the provision in the above paragraph on long-term capital accumulation if and to the extent that conditions or requirements are attached to donations to the foundation that stipulate that donated funds can or shall, in whole or in part, be distributed for investment purposes.
At least one-tenth of the annual return shall be transferred to irrevocable capital. The rest of the return is to be transferred to unrestricted capital.
The Foundation shall have a Board consisting of five members. The University of Bergen and Helse Bergen Health Trust shall each appoint one Board member. Trond Mohn shall appoint three board members, including the Chair of the Board. The Board may be expanded by two members, from five to seven members. In that case, the University of Bergen and Helse Bergen Health Trust shall jointly appoint one member and Trond Mohn shall appoint one member. Trond Mohn may transfer his right to appoint Board members to the Board or other parties if he so wishes.
The Board members shall represent a broad range of backgrounds in terms of gender, expertise and public interests. In order to achieve this goal, the appointment of Board members shall take place in consultation with the Chair of the board. At least one of the five Board members should have professional expertise in or experience of investment management.
The University of Bergen and Helse Bergen Health Trust shall jointly appoint one Deputy Board member. This Deputy Board member will attend Board meetings when at least one of the two Board members appointed by these organisations is unable to attend. Trond Mohn shall likewise appoint one Deputy Board member who will attend Board meetings when at least one of the three Board members appointed by him is unable to attend.
The Board members serve for a term of four years. Board members may be re-appointed once or more.
In matters that fall within the scope of Article 2, the board shall obtain expert statements before making its decision.
The Board may establish one or more Advisory Committees to provide expert contributions in connection with the preparation of matters for consideration by the Board as mentioned in Article 2.
The Board shall appoint a Business Manager.
Amendments to these statutes (conversion) can be proposed by the Board and submitted to the competent supervisory authority for approval in accordance with the provisions of the Norwegian Foundations Act.
Bergen, 1 January 2019.